US EditionPublished • loading... • Updated
ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
The $1.04 billion deal includes $80 million upfront and royalties for Sanofi to develop ADEL-Y01, a first-in-class antibody targeting toxic tau in Alzheimer's disease.
- ADEL, Inc. granted Sanofi an exclusive worldwide license for ADEL-Y01 on Dec. 15, 2025, including an $80 million upfront payment and potential value up to $1.04 billion.
- Targeting tau acetylation at Lysine-280, ADEL-Y01 selectively inhibits toxic tau aggregation while preserving normal tau function, leveraging ADEL's proprietary platform for disease-relevant protein acetylation.
- ADEL, Inc. led discovery and preclinical development and is advancing ADEL-Y01 into a global Phase 1 trial under a U.S. FDA-approved IND, co-developed with Oscotec Inc. since 2020.
- Under the agreement, ADEL, Inc. will receive milestone payments contingent on development and commercial milestones and tiered royalties on net sales that can reach double-digit percentages.
- Sanofi's Erik Wallstroem described ADEL's approach as promising and said the company will advance ADEL-Y01 through development, highlighting its strategic significance.
Insights by Ground AI
37 Articles
37 Articles
Bennington Banner+35 Reposted by 35 other sources
ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
Deal includes $80 million upfront payment, with total potential value up to $1.04 billion plus royaltiesADEL grants exclusive worldwide rights for acetylated tau-targeting antibody 'ADEL-Y01' to SanofiADEL's proprietary platform targeting tau modification (acetylation) as a breakthrough approach for neurodegenerative diseases
Coverage Details
Total News Sources37
Leaning Left3Leaning Right3Center10Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
L 19%
C 62%
R 19%
Factuality
To view factuality data please Upgrade to Premium
